This report details practical management techniques and dosing strategies for using bivalirudin as an alternative anticoagulant during cardiopulmonary bypass in patients with or at risk for heparin-induced thrombocytopenia.
Answers are grounded in this paper and cite their sources.
May guide bivalirudin dosing in CPB for HIT; leaves open need for prospective validation.
Bivalirudin is a short-acting direct thrombin inhibitor that has been used in cardiac surgical patients with heparin-induced thrombocytopenia (HIT) or suspected HIT. Although no direct thrombin inhibitor is indicated for anticoagulation during cardiac surgery in patients with heparin-induced thrombocytopenia (HIT) or suspected HIT, use of heparin-alternatives are increasing as the awareness of HIT increases. Reports of anticoagulation with bivalirudin are sporadic, however, with variable dosing and management strategies. In this report, we describe our management techniques for cardiopulmonary bypass with bivalirudin based upon our personal experience. Although the reported clinical experience with bivalirudin in cardiac surgery is reviewed, operative techniques for the perfusionist/surgeon team are discussed in detail. We recognize that the use of bivalirudin during cardiopulmonary bypass is evolving and modifications of technique will undoubtedly occur as further data and experience accumulate.
No takes yet. Share an insight, caveat, or question.
Veale et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: